Linked e-resources
Details
Table of Contents
Preface; Contents; Contributors; Chapter 1: Angiotensin Converting Enzyme Inhibitors and AT1 Antagonists for Treatment of Hypertension; RAS Inhibition and Blood Pressure Lowering; RAS Inhibition and Hypertension-Related Metabolic Abnormalities; Dyslipidemias; Metabolic Syndrome and Obesity; Insulin Resistance and Diabetes; RAS Inhibition and Hypertension-Related TOD; Left Ventricular Hypertrophy; Chronic Kidney Disease; Dual RAS Inhibition; Atherosclerosis; RAS Inhibition and CV Events; Stroke; Myocardial Infarction; RAS Inhibitors and Mortality; References
Chapter 2: ACE Inhibitor and Renin-Angiotensin System the Cornerstone of Therapy for Systolic Heart Failure; Definition of Heart Failure; Epidemiology, Incidence, Prevalence and Natural History of Heart Failure; Aetiology of Heart Failure; Pathophysiology of Heart Failure; The Renin-Angiotensin System; Focus on Blockade of the Renin-Angiotensin System; Trials That Support the Use of Angiotensing-Converting Enzyme Inhibitors; ACE-Inhibitors Compared with Angiotensin Receptor Blockers; Use of the ACE Inhibitors in the Hearth Failure: ESC and ACCF/AHA Guidelines; References
Chapter 3: Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure; Introduction; Choice of RAAS Inhibitors in Patients with Chronic Kidney Disease; Studies in Diabetic or Non-diabetic Proteinuric Kidney Disease; Studies in Non-proteinuric Kidney Disease; High Doses of RAAS-Inhibitors or Dual RAAS Blockade; Choice of Antihypertensive Treatment in Patients with Diabetes Mellitus; Effects of Antihypertensive Agents on Insulin Sensitivity; Effects of Antihypertensive Agents on New-Onset DM
Data from Hypertension Outcome Trials Evaluating New-Onset DM as a Secondary Outcome; Data from Trials and Meta-analyses Investigating the Effects of Antihypertensive Agents on Metabolic Parameters and New-Onset DM; New-Onset DM and Cardiovascular Risk; Conclusion; References; Chapter 4: Target Organ Damage and RAAS Blockade; Introduction; RAAS Dysregulation and Target Organ Damage; Monotherapy with ACEIs; Monotherapy with ARBs; Dual Therapy; Comparison Between ACEIs and ARBs; Conclusions; References; Index
Chapter 2: ACE Inhibitor and Renin-Angiotensin System the Cornerstone of Therapy for Systolic Heart Failure; Definition of Heart Failure; Epidemiology, Incidence, Prevalence and Natural History of Heart Failure; Aetiology of Heart Failure; Pathophysiology of Heart Failure; The Renin-Angiotensin System; Focus on Blockade of the Renin-Angiotensin System; Trials That Support the Use of Angiotensing-Converting Enzyme Inhibitors; ACE-Inhibitors Compared with Angiotensin Receptor Blockers; Use of the ACE Inhibitors in the Hearth Failure: ESC and ACCF/AHA Guidelines; References
Chapter 3: Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure; Introduction; Choice of RAAS Inhibitors in Patients with Chronic Kidney Disease; Studies in Diabetic or Non-diabetic Proteinuric Kidney Disease; Studies in Non-proteinuric Kidney Disease; High Doses of RAAS-Inhibitors or Dual RAAS Blockade; Choice of Antihypertensive Treatment in Patients with Diabetes Mellitus; Effects of Antihypertensive Agents on Insulin Sensitivity; Effects of Antihypertensive Agents on New-Onset DM
Data from Hypertension Outcome Trials Evaluating New-Onset DM as a Secondary Outcome; Data from Trials and Meta-analyses Investigating the Effects of Antihypertensive Agents on Metabolic Parameters and New-Onset DM; New-Onset DM and Cardiovascular Risk; Conclusion; References; Chapter 4: Target Organ Damage and RAAS Blockade; Introduction; RAAS Dysregulation and Target Organ Damage; Monotherapy with ACEIs; Monotherapy with ARBs; Dual Therapy; Comparison Between ACEIs and ARBs; Conclusions; References; Index